Up to 90% of AML patients have c-kit expression correlating with poor prognosis and resistance to chemotherapy (15, 16), making this receptor an attractive target for malignant myeloid cell and leukemic stem cell (LSC) ablation. Here, KIT is linked to acute myeloid leukemia.